Mero-83Homo sapiens (Human)Cancer cell line
Also known as: MERO83
🤖 AI SummaryBased on 2 publications
Quick Overview
Human malignant mesothelioma cell line for cancer research.
Detailed Summary
Mero-83 is a human malignant mesothelioma cell line established from patient-derived tumor samples. It is used in research to study the molecular mechanisms of mesothelioma, including genetic alterations and signaling pathways. The cell line exhibits characteristics of malignant mesothelioma, such as abnormal karyotypes and specific intermediate filament expression. It has been utilized in studies investigating the Hippo signaling pathway and its role in tumor progression. Mero-83 is valuable for in vitro studies on mesothelioma biology and potential therapeutic targets.
Research Applications
Cancer researchMolecular mechanisms of mesotheliomaHippo signaling pathway studiesGenetic and cytogenetic analysis
Key Characteristics
Abnormal karyotypesIntermediate filament expressionMalignant mesothelioma origin
Generated on 6/19/2025
Basic Information
| Database ID | CVCL_2595 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Male |
Disease Information
| Disease | Pleural mesothelioma |
|---|---|
| Lineage | Pleura |
| Subtype | Pleural Mesothelioma, Biphasic Type |
| OncoTree Code | PLBMESO |
DepMap Information
| Source Type | Sigma-Aldrich |
|---|---|
| Source ID | ACH-001560_source |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X,Y
CSF1PO
11,13
D13S317
9,12
D16S539
11,12
D18S51
15
D21S11
27,30
D3S1358
14
D5S818
11,12
D7S820
9
D8S1179
12,14
FGA
25
Penta D
12,14
Penta E
9,16
TH01
7
TPOX
8,11
vWA
18,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
Asamura H., Gemma A., Yamada T.
J. Thorac. Oncol. 10:844-851(2015).